Milk production change following clinical mastitis and reproductive performance compared among J5 vaccinated and control dairy cattle.
Naturally occurring cases of bovine clinical mastitis (CM) were studied among J5 vaccinates and controls on 3 commercial dairy farms. Milk production change and reproductive performance following CM were compared between the 2 groups. Among 306 controls and 251 vaccinates, there were 221 new cases of CM affecting 120 cows; 437 lactations never had a case of CM. Environmental pathogens made up 90% (159/176) of etiologic agents isolated. Change in daily milk production following CM was associated with J5 vaccination, days in milk (DIM) at onset of CM, and herd effect as well as each 2-way interaction between the 3 factors. The adjusted daily milk for 21 d following CM was 7.6 kg greater among J5 vaccinates than controls; however, this protective effect of vaccination waned with increasing DIM at onset of CM. A mixed linear model with autoregressive order 1 [AR(1)] correlation structure estimated the daily milk production of any cow (whether or not she had CM) on a given DIM. Cows with CM caused by nonagalactiae streptococci, Staphylococcus aureus, Escherichia coli, or Klebsiella lost significant daily milk production for the entire lactation relative to nonmastitic cows. Another mixed linear model for only coliform CM cases (E. coli, Klebsiella, and Enterobacter) within the first 50 DIM showed milk loss for 21 d following coliform CM to be significantly less for J5 vaccinates than for controls, by 6 to 15 kg per day. Cows were significantly less likely to become pregnant if they had CM caused by E. coli (42% pregnant) or Streptococcus spp. (38% pregnant), whereas 78% (342/437) of cows with no mastitis conceived. Days open (number of days from calving until pregnancy) averaged 131 d for cows with no CM and 162 d for cows that had at least one case of CM. Days until conception, days until last breeding, days open, times bred, and percentage of cows pregnant by 200 DIM were not changed with J5 vaccination. Nonetheless, an important benefit of the use of J5 bacterin appears to be reduction of the loss of daily milk production following CM, whether all cases or only those caused by coliform bacteria were considered.
Wilson
D J
DJ
Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan 84321, USA. David.Wilson@usu.edu
Grohn
Y T
YT
Bennett
G J
GJ
González
R N
RN
Schukken
Y H
YH
Spatz
J
J
D000818:Animals; D001419:Bacteria / Q000302:isolation & purification; D001424:Bacterial Infections / Q000276:immunology / Q000382:microbiology / Q000662:veterinary*; D001428:Bacterial Vaccines / Q000276:immunology*; D002417:Cattle; D003612:Dairying; D005260:Female; D007774:Lactation; D016014:Linear Models; D008070:Lipopolysaccharides / Q000276:immunology*; D008414:Mastitis, Bovine / Q000382:microbiology / Q000517:prevention & control*; D008892:Milk / Q000378:metabolism*; D011247:Pregnancy; D012098:Reproduction / Q000276:immunology / Q000502:physiology*; D014611:Vaccination / Q000009:adverse effects / Q000662:veterinary*
D001428:Bacterial Vaccines; D008070:Lipopolysaccharides; C485022:lipopolysaccharide, E coli J5